Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
about
Getting the balance right: Established and emerging therapies for major depressive disordersVariability in metabolism of imipramine and desipramine using urinary excretion data.Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application.
P2860
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@en
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@nl
type
label
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@en
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@nl
prefLabel
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@en
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@nl
P2093
P356
P1476
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
@en
P2093
Daniel Dugan
Sarah J Billups
Thomas Delate
P2860
P304
P356
10.1002/PDS.1697
P577
2009-03-01T00:00:00Z